The immune enhancer granulocyte-macrophage colony stimulating factor (GM-CSF) sagramostim significantly improved symptoms in 80% of 15 patients with moderate to severe Crohn’s disease and induced clinical remission in more than 50%, according to a research letter in the Nov. 9 issue of The Lancet.
Symptoms recurred with discontinuation of the drug, also known by the trade name Leukine, but then resolved with reinstitution of therapy. “At first blush, the idea of priming the immune system in patients with Crohn’s disease sounds sort of like throwing oil on a fire,” senior author Joshua R. Korzenik, MD, from Washington University School of Medicine in St. Louis, Missouri, says in a news release. “You might compare it to proposing a high cholesterol diet to treat heart disease.”
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!